{
    "doi": "https://doi.org/10.1182/blood.V122.21.5270.5270",
    "article_title": "Azacitidine In The Treatment Of Ph- Myeloproliferative Neoplasms In Blastic Phase: The Experience Of Gruppo Laziale For The Study Of Ph- SMPC ",
    "article_date": "November 15, 2013",
    "session_type": "635. Myeloproliferative Syndromes: Basic Science",
    "abstract_text": "Prognosis of patients with myeloproliferative neoplasms developing blast phase (MPN-BP) is very poor. Median survival of these patients is about 2-3 months (Cervantes F, Acta Hemathol 1991; Mesa RA, Blood 2005; Kantajian HM, Leukemia 1997; Tam CS, Blood 2008) and nowadays no drug can induce a durable complete response (CR) in patients who are not candidate to BMT. A phase II study (Thepot S., Blood 2010, 116, 3735) recently reported on 54 patients with MPN-BP treated with 5-AZA, showing a median survival of 9 months with an Overall Response Rate (ORR) of 52% (24% complete response). Material and Methods To highlight the role of 5-AZA in this subset, we evaluated retrospectively 16 patients (M/F 12/4, median age 63.5 years, range 51 - 81) with MPN-BP according to standard definition (Mascarenhas J et al., Leuk Res. 2012 Dec;36(12):1500-4) treated with 5-AZA in the last 3 years and reported in the database of Gruppo Laziale for the study of Ph- SMPC. Primitive MPN diagnosis was Essential Thrombocythemia in 5 cases, Primary Myelofibrosis in 6, Polycythemia Vera in 1 and MDS/MPN in 4; the JAK-2 V617F mutation was present in 7/14 patients tested (50%); all, but 1, patients received a previous treatment during chronic myeloproliferative phase [12 patients with Hydroxyurea (HU) alone, 1 with HU + Anagrelide, 1 with HU + Pipobroman and 1 with Melphalan + Allogeneic bone marrow transplantation]. Median time from diagnosis to BP evolution was 47 months (range 12 - 317). All patients were treated with 5-AZA at the dosage of 75 mg/m 2 : as to the schedule, 13 patients received a 7-day schedule and 3 patients a 5-day schedule every 28 days. At the time of evolution, median WBC value was 17.1 x 10 6 /L (range 5.0\u201389.5), median Hb level 9.9 g/dl (range 6.6\u201312.7) and median PLT value 155 x 10 6 /L (range 7\u2013434). Two patients died early after 5-AZA initiation from pulmonary fungal infection and respiratory failure respectively, 4 patients had a disease progression, 4 patients a stable disease, 2 patients(14%) had an hematological improvement and 4 pts (28.5%) a complete response after 4, 4, 5, and 12 months; median survival of patients in CR is 19.6 months. The overall survival from BP evolution was 8.1 months (range 1\u201349.5 months) and 3/4 patients in CR are still alive after 15, 24 and 49.5 months, respectively. Conclusions Our data confirm the relative efficacy and safety of 5-AZA in this group of patients with otherwise dismal prognosis, underlining the possible achievement of long-lasting responses in a sizeable portion of them. Disclosures: Off Label Use: Bendamustine.",
    "topics": [
        "azacitidine",
        "myeloproliferative disease",
        "complete remission",
        "anagrelide",
        "bendamustine",
        "blast phase",
        "bone marrow transplantation, allogeneic",
        "brachial plexus neuritis",
        "disease progression",
        "hydroxyurea"
    ],
    "author_names": [
        "Alessandro Andriani",
        "Roberto Latagliata, MD",
        "Maria Teresa Voso, M.D.",
        "Nicoletta Villiv\u00e0",
        "Fabrizio Ciccone",
        "Cristina Andrizzi, MD",
        "Cinzia De Gregoris",
        "Francesco Buccisano, MD",
        "Angelo De Blasio",
        "Barbara Anaclerico, MD",
        "Giuseppe Avvisati, MD, PhD",
        "Antonino Bagnato, MD",
        "Michele Cedrone",
        "Giuseppe Cimino, MD",
        "Ignazio Majolino",
        "Prof",
        "Enrico Montefusco",
        "Antonio Spadea",
        "Giuliana Alimena",
        "Marco Montanaro"
    ],
    "author_dict_list": [
        {
            "author_name": "Alessandro Andriani",
            "author_affiliations": [
                "Hematology, Nuovo Regina Margherita Hospital, Roma, Italy, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Roberto Latagliata, MD",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Teresa Voso, M.D.",
            "author_affiliations": [
                "Istituto di Ematologia, Universit\u00e0 Cattolica S. Cuore, Rome, Italy, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicoletta Villiv\u00e0",
            "author_affiliations": [
                "Hematology, Nuovo Regina Margherita Hospital, Rome, Italy, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabrizio Ciccone",
            "author_affiliations": [
                "Santa Maria Goretti Hospital - Hematology, Latina, Italy, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Andrizzi, MD",
            "author_affiliations": [
                "UOS of Hematology, Santo Spirito in Sassia Hospital, Rome, Italy, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cinzia De Gregoris",
            "author_affiliations": [
                "Belcolle Hospital, Viterbo, Hematology, Viterbo, Italy, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Buccisano, MD",
            "author_affiliations": [
                "Hematology, University Tor Vergata, Rome, Italy, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Angelo De Blasio",
            "author_affiliations": [
                "Hematology Unit, Santa Maria Goretti Hospital, Latina, Italy, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barbara Anaclerico, MD",
            "author_affiliations": [
                "UOC of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Avvisati, MD, PhD",
            "author_affiliations": [
                "Hematology, Campus Biomedico University, Rome, Italy, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonino Bagnato, MD",
            "author_affiliations": [
                "Hematology, Pertini Hospital, Rome, Italy, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Cedrone",
            "author_affiliations": [
                "Hematology, Azienda Ospedaliera S.Giovanni Addolorata, Roma, Italy, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Cimino, MD",
            "author_affiliations": [
                "Hematology, Sapienza University, Polo Pontino, Rome, Italy, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ignazio Majolino",
            "author_affiliations": [],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Prof",
            "author_affiliations": [
                "HEMATOLOGY AND STEM CELL TRANSPLANTATION, SAN CAMILLO FORLANINI HOSPITAL, ROME, Italy, "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Enrico Montefusco",
            "author_affiliations": [
                "Hematology, Sant'Andrea Hospital, Rome, Italy, "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Spadea",
            "author_affiliations": [
                "Regina Elena National Cancer Institute, Hematology, IFO, Rome, Italy, "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuliana Alimena",
            "author_affiliations": [
                "Department of Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Montanaro",
            "author_affiliations": [
                "Hematology, Belcolle Hospital, Viterbo, Italy"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-26T06:46:23",
    "is_scraped": "1"
}